Immuron (ASX: IMC) is an Australian-listed company in the Healthcare sector with a market capitalisation of $8.3M and the 1550th-largest security on the ASX by market capitalisation. The IMC share price is $0.032, up 6.67% today and down 53.85% over the past 12 months. Shares have traded between $0.026 and $0.098 over the past 52 weeks. In its most recent reported period (ending 31 Dec 2025), Immuron reported revenue of $4.2M and a net loss of $1.9M.
About Immuron Limited
Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Research and Development, and Hyperimmune Products—the company serves markets in Australia, Israel, Canada, the United States, and other international regions. Its current product portfolio includes Travelan, an over-the-counter remedy aimed at reducing the likelihood of travelers' diarrhea and minor gastrointestinal complaints, which also functions as a dietary supplement for digestive well-being and gut protection. Another offering, Protectyn, is an immune supplement formulated to bolster healthy digestive function and liver support. Beyond its commercialized products, Immuron is actively progressing several pipeline candidates. Travelan (IMM-124E) is currently undergoing a Phase III registration trial in the United States for the prevention of travelers' diarrhea, alongside a Phase II field trial for the same indication, and has demonstrated antiviral efficacy against SARS-CoV-2. Concurrently, IMM-529 is in Phase I/IIa clinical trials, targeting patients with recurrent Clostridium difficile infections. The company has also established key research alliances, including an agreement with the Naval Medical Research Center to develop and clinically evaluate a therapeutic agent against Campylobacter and enterotoxigenic Escherichia coli infections, and a collaborative effort with the Walter Reed Army Institute of Research to create an oral treatment for shigellosis.
CEO
Steven George Lydeamore
